Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal L Oden

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
JAMA Ophthalmology|March 24, 2022
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18Ingrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Ophthalmology|May 23, 2023
SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein OcclusionIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
American Journal of Ophthalmology|May 5, 2024
Association of Retinal Thickness at Month 1 Postrandomization With Later Thickness and Visual Acuity in Central Vein OcclusionIngrid U Scott, Neal L Oden, Michael S Ip, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|November 29, 2021
SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusionIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Pediatrics|April 5, 2005
A pulmonary score for assessing the severity of neonatal chronic lung diseaseAshima Madan, Beverly S Brozanski, Cynthia H Cole, et al.
The American Journal of Drug and Alcohol Abuse|August 23, 2011
Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trialsNeal L Oden, Paul C VanVeldhuisen, Paul G Wakim, et al.
American Journal of Ophthalmology|July 25, 2016
SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein OcclusionIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
American Journal of Ophthalmology|August 14, 2009
SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe designIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|January 8, 2021
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trialRahul N Khurana, Neal L Oden, Paul C VanVeldhuisen, et al.
JAMA Ophthalmology|October 11, 2019
Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical TrialIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
JAMA Ophthalmology|March 24, 2022
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18Ingrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Ophthalmology|May 23, 2023
SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein OcclusionIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
American Journal of Ophthalmology|May 5, 2024
Association of Retinal Thickness at Month 1 Postrandomization With Later Thickness and Visual Acuity in Central Vein OcclusionIngrid U Scott, Neal L Oden, Michael S Ip, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|November 29, 2021
SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusionIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Pediatrics|April 5, 2005
A pulmonary score for assessing the severity of neonatal chronic lung diseaseAshima Madan, Beverly S Brozanski, Cynthia H Cole, et al.
The American Journal of Drug and Alcohol Abuse|August 23, 2011
Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trialsNeal L Oden, Paul C VanVeldhuisen, Paul G Wakim, et al.
American Journal of Ophthalmology|July 25, 2016
SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein OcclusionIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
American Journal of Ophthalmology|August 14, 2009
SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe designIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|January 8, 2021
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trialRahul N Khurana, Neal L Oden, Paul C VanVeldhuisen, et al.
JAMA Ophthalmology|October 11, 2019
Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical TrialIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Pageof 6